Bayer AG has received U.S. FDA approval for a Factor VIII hemophilia drug, called Jivi.
Jivi is used in preventative treatment of hemophilia A and is also approved for on-demand treatment. It is the third FDA-approved hemophilia A treatment in Bayer’s hemophilia portfolio.
Bayer has also submitted marketing authorization applications for Jivi in the European Union and Japan.
Read the press release